Key Insights

Highlights

Treatment Research

1 treatments under study, led by Mirdametinib

Related Conditions

Often studied with 12 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 2 (1)

Trial Status

Not Yet Recruiting1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07891286Phase 2Not Yet Recruiting

Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults

NCT04548817Recruiting

Neurocutaneous Melanocytosis Registry

Showing all 2 trials

Research Network

Common Treatments

  • Mirdametinib1

Active Sponsors

  • Memorial Sloan Kettering Cancer Center1
  • National Cancer Institute Nci1

Related Conditions

  • Pediatric Tumors1
  • Astrocytoma1
  • Nf11
  • Lgcmn1
  • Solid Tumor1

Activity Timeline